The litigation focuses on widely prescribed GLP-1 drugs, including: These medications, used for treatment of type 2 diabetes and weight management, have been alleged in filed cases to increase the risk of sudden optic nerve ischemia resulting in partial or complete vision loss
Learn more: To view or add a comment, sign in More Relevant Posts When the Wegovy pill was approved in December 2025, it became the first oral GLP-1 approved for weight loss
A realistic timeline: 48 weeks: early subjective changes may appear 812 weeks: body-composition changes may become more noticeable 36 months: better window to evaluate progress Ipamorelin should not be marketed as a substitute for semaglutide, tirzepatide, or clinically indicated obesity treatment
Antioxidants act as scavengers of free radicals
Adequate hydration to help with digestion, energy, and appetite regulation